Asymptomatic hyperuricemia: is it really asymptomatic?
Yip K, Cohen RE, Pillinger MH.
Curr Opin Rheumatol. 2020 Jan;32(1):71-79. doi: 10.1097/BOR.0000000000000679.
Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective.
Moszczuk B, Życińska K, Mucha K.
Arch Immunol Ther Exp (Warsz). 2024 Nov 29;72(1). doi: 10.2478/aite-2024-0024. eCollection 2024 Jan 1.
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Waheed Y, Yang F, Sun D.
Korean J Intern Med. 2021 Nov;36(6):1281-1293. doi: 10.3904/kjim.2020.340. Epub 2021 Jul 8.
How should we manage asymptomatic hyperuricemia?
Chalès G.
Joint Bone Spine. 2019 Jul;86(4):437-443. doi: 10.1016/j.jbspin.2018.10.004. Epub 2018 Oct 11.
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases.
Fiori E, De Fazio L, Pidone C, Perone F, Tocci G, Battistoni A, Barbato E, Volpe M, Gallo G; Young Group of The Italian Society of Cardiovascular Prevention (SIPREC).
J Hypertens. 2024 Oct 1;42(10):1665-1680. doi: 10.1097/HJH.0000000000003807. Epub 2024 Jul 10.
Asymptomatic hyperuricemia: is it time to intervene?
Paul BJ, Anoopkumar K, Krishnan V.
Clin Rheumatol. 2017 Dec;36(12):2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct 4.
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P, Chaiyakunapruk N, McKay G, Attia J, Thakkinstian A.
BMC Nephrol. 2022 Jun 23;23(1):223. doi: 10.1186/s12882-022-02850-3.
Management of hyperuricemia in asymptomatic patients: A critical appraisal.
Brucato A, Cianci F, Carnovale C.
Eur J Intern Med. 2020 Apr;74:8-17. doi: 10.1016/j.ejim.2020.01.001. Epub 2020 Jan 15.
Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study.
Barnini C, Russo E, Leoncini G, Ghinatti MC, Macciò L, Piaggio M, Viazzi F, Pontremoli R.
Metabolites. 2025 Jan 2;15(1):11. doi: 10.3390/metabo15010011.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
